Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001)

被引：1
|
作者：
Liu, Jing
Wu, Junwei
Zhu, Liangjun
Yan, Jun
Mao, Yong
Tang, Xinyu
Zhu, Lingjun
Jiang, Hong
Wei, Xiaowei
Shangguan, Chengfang
Xi, Wenqi
Shi, Yan
Shi, Min
Zhou, Chenfei
Yang, Hui
Zhang, Jun
机构：
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China
[2] Jiansu Canc Hosp, Dept Oncol, Nanjing, Peoples R China
[3] Shanghai Univ Med & Hlth Sci, Jiading Cental Hosp, Dept Oncol, Shanghai, Peoples R China
[4] Jiannan Univ, Affiliated Hosp, Dept Oncol, Wuxi, Jiangsu, Peoples R China
[5] Ruijin Hosp, Wuxi Branch, Dept Oncol, Wuxi, Jiangsu, Peoples R China
[6] Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China
[7] Tongji Univ, Tongji Hosp, Dept Oncol, Shanghai, Peoples R China
[8] Nanjing First Hosp, Dept Oncol, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS229
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS229
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Update results from ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC-A single-arm, multicenter, phase II clinical trial.
    Yan, Jin
    Han, Yunwei
    Zhang, Li
    Jin, Yongdong
    Sun, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Multicenter phase 2 trial (RENOBATE)
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Kim, Hyung-Don
    Ryu, Min-Hee
    Kang, Beodeul
    Chon, Hong Jae
    Hong, Jung Yong
    Lim, Ho Yeong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [23] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [24] Update of a phase II, multicenter clinical trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.
    Yan, Jin
    Han, Yunwei
    Zhang, Li
    Jin, Yongdong
    Sun, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15566 - E15566
  • [25] A multicenter phase II trial of tumor treating fields plus chemotherapy for first-line treatment of gastric adenocarcinoma
    Li, Jin
    Yeo, Winnie
    Lam, Ka-On
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [26] Benmelstobart With Anlotinib Plus Chemotherapy as First-Line Therapy for ES-SCLC: A Randomized, Double-Blind, Phase 3 Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (10) : 6 - 7
  • [27] Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial
    Cheng, Y.
    Yang, R.
    Chen, J.
    Zhang, W.
    Xie, C.
    Hu, Q.
    Zhou, N.
    Huang, C.
    Wei, S.
    Sun, H.
    Li, X.
    Yu, Y.
    Lai, J.
    Yang, H.
    Fang, H.
    Chen, H.
    Zhang, P.
    Gu, K.
    Wang, Q.
    Shi, J.
    Yi, T.
    Xu, X.
    Ye, X.
    Wang, D.
    Xie, C.
    Liu, C.
    Zheng, Y.
    Lin, D.
    Zhuang, W.
    Lu, P.
    Yu, G.
    Li, J.
    Gu, Y.
    Li, B.
    Wu, R.
    Jiang, O.
    Wang, Z.
    Wu, G.
    Lin, H.
    Zhong, D.
    Xu, Y.
    Shu, Y.
    Wu, D.
    Chen, X.
    Wang, J.
    Wang, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S44 - S44
  • [28] First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases - Invited critique
    Kennedy, Gregory
    Nelson, Heidi
    ARCHIVES OF SURGERY, 2008, 143 (04) : 358 - 358
  • [29] Efficacy of first-line radiofrequency ablation combined with systemic chemotherapy plus targeted therapy for initially unresectable colorectal liver metastases
    Kong, Yaqing
    Huang, Xiaoyu
    Peng, Gang
    Cao, Xiaojing
    Zhou, Xiang
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2025, 42 (01)
  • [30] A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus Hermann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345